Stefanie K. Gräfe

Stefanie K. Gräfe

Auto-generated profile, based on publicly available information

Stefanie K. Gräfe

Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2024 in Science
Verified
Journal Article
Closed access
ILImke Liebold
Imke Liebold
AJAmirah Al Jawazneh
Amirah Al Jawazneh
CCChristian Casar
Christian Casar
CLClarissa Lanzloth
Clarissa Lanzloth
SLStephanie Leyk
Stephanie Leyk
LBLidia Bosurgi
Lidia Bosurgi
Macrophages are functionally heterogeneous cells essential for apoptotic cell clearance. Apoptotic cells are defined by homogeneous characteristics, ignoring their original cell lineage identity. We found that in an interleukin-4 (IL-4)–enriched environment, the sensing of apoptotic neutrophils by macrophages triggered their tissue remodeling signature. Engulfment of apoptotic hepatocytes promoted a tolerogenic phenotype, whereas phagocytosis of T cells had little effect on IL-4–induced gene expression. In a mouse model of parasite-induced pathology, the transfer of macrophages conditioned with IL-4 and apoptotic neutrophils promoted parasitic egg clearance. Knockout of phagocytic receptors required for the uptake of apoptotic neutrophils and partially T cells, but not hepatocytes, exacerbated helminth infection. These findings suggest that the identity of apoptotic cells may contribute to the development of distinct IL-4–driven immune programs in macrophages.

22 September 2022 in Blood
Verified
Journal Article
Open access
PDF file
Livio PaganoLivio Pagano
Livio Pagano
JSJon Salmanton-García
Jon Salmanton-García
FMFrancesco Marchesi
Francesco Marchesi
OBOLA BLENNOW
OLA BLENNOW
MSMaria Gomes da Silva
Maria Gomes da Silva
OCOliver A. Cornely
Oliver A. Cornely
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.

28 June 2022 in American Journal of Hematology
Verified
Journal Article
Open access
OBOLA BLENNOW
OLA BLENNOW
JSJon Salmanton-García
Jon Salmanton-García
PNPiotr Nowak
Piotr Nowak
FIFederico Itri
Federico Itri
JDJaap Van Doesum
Jaap Van Doesum
Livio PaganoLivio Pagano
Livio Pagano

2 June 2020 in Mycoses
Verified
Journal Article
Open access
PDF file
JSJannik Stemler
Jannik Stemler
KHKamal Hamed
Kamal Hamed
JSJon Salmanton-García
Jon Salmanton-García
ARAli Rezaei-Matehkolaei
Ali Rezaei-Matehkolaei
SGStefanie K. Gräfe
Stefanie K. Gräfe
OCOliver A. Cornely
Oliver A. Cornely
Summary: Background: Regional differences in the underlying causes, manifestations and treatment of mucormycosis have been noted in studies covering Europe, Asia and South America.Objectives: To review cases of mucormycosis across the Middle East and North Africa (MENA) region in order to identify epidemiological, treatment and outcome trends in this region.Patients/Methods: Cases of proven or probable invasive mucormycosis from the region were identified from the FungiScope® database and the medical literature. For each case, information on underlying condition, site of infection, pathogenic species, therapeutic intervention, type of antifungal therapy and outcome were analysed.Results: We identified 310 cases of mucormycosis in the MENA region. The number of reported cases increased by decade from 23 before 1990 to 127 in the 2010s. In this region, the most common underlying conditions associated with mucormycosis were diabetes mellitus (49.7%) and conditions associated with immunosuppression (46.5%). The majority of patients received treatment with antifungals (93.5%), with a large proportion treated with both antifungals and surgery (70.6%). Overall mortality rates decreased from 47.8% before 1990 to 32.3% in the 2010s.Conclusions: The number of reported cases of mucormycosis in the MENA region has risen over the past few decades, in line with increases in the number of patients with underlying conditions associated with this infection. Although the majority of patients received treatment with antifungal therapies and/or surgery, the associated mortality rate remains high and there is a clear need for more effective prevention and treatment strategies in the MENA region.

13 June 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
JDJaap A. van Doesum
Jaap A. van Doesum
JSJon Salmanton-García
Jon Salmanton-García
FMFrancesco Marchesi
Francesco Marchesi
RBRoberta Di Blasi
Roberta Di Blasi
IFIker Falces-Romero
Iker Falces-Romero
Livio PaganoLivio Pagano
Livio Pagano
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19–caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.

14 January 2021 in Biomarkers in Medicine
Verified
Journal Article
Closed access
ARAlina M Rüb
Alina M Rüb
ATAnastasia Tsakmaklis
Anastasia Tsakmaklis
SGStefanie K Gräfe
Stefanie K Gräfe
Marie-Christine SimonMarie-Christine Simon
Marie-Christine Simon
MVMaria Jgt Vehreschild
Maria Jgt Vehreschild
IWIrene Wuethrich
Irene Wuethrich
The association of gut microbiota dysbiosis with various human diseases is being substantiated with increasing evidence. Metabolites derived from both, microbiota and the human host play a central ...